STAY CURRENT with FDA-Approved Immunotherapy Treatments from your Office or Home

MADISON, WIS., VIRTUAL ACI PROGRAM

INFORMATION

Thursday, Sept. 24, 2020
3–8:30 p.m. CDT

FREE for healthcare professionals, students, patients and patient advocates, the Society for Immunotherapy of Cancer (SITC) Advances in Cancer Immunotherapy™ (ACI) programs are CME-, CNE-, CPE- and MOC-certified and presented by local authorities in tumor immunology and cancer immunotherapy.

ORGANIZERS:
Christian Capitini, MD – University of Wisconsin Carbone Cancer Center
Zachary Morris, MD, PhD – University of Wisconsin Carbone Cancer Center
Carissa Dolens, DNP, AGPCNP-BC, APNP, OCN – University of Wisconsin Carbone Cancer Center

ACCREDITATION INFORMATION
AMA Credit Designation
This activity has been approved for AMA PRA Category 1 Credit(s)™.
Pharmacist Credit Designation
This activity is eligible for ACPE credit, see final CPE activity announcement for specific details.
Nursing Credit Designation
This activity is eligible for ANCC contact hours, see final CNE activity announcement for specific details.

MADISON LIVE VIRTUAL ACI PROGRAM TAKEAWAYS
In addition to networking with fellow colleagues, highlights of the program include:
• Interactive, virtual setting to connect with local faculty and organizers
• Learning how to treat patients with FDA-approved immunotherapies
• A deep dive into identifying and managing irAEs
• COVID-19 considerations from the speakers’ direct experience
• Interpreting new clinical data supporting the use of checkpoint inhibitors, CAR T therapies, cytokines, oncolytic viruses and vaccines

Attendees will able to connect with regional immunotherapy experts during these interactive virtual programs, in subsequent quarterly webinars and through a dedicated SITC CONNECT online community.

REGISTER YOURSELF AND SHARE WITH A COLLEAGUE to ensure your entire team is up to date on the latest FDA-approved immunotherapy treatments

For full accreditation information and to register for this event, please visit:
sitcancer.org/aci/madison2020

The 2020–2021 ACI series is jointly provided by the Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer in collaboration with the American Academy of Emergency Medicine, the Association of Community Cancer Centers and the Hematology/Oncology Pharmacy Association.

The 2020–2021 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc. and Merck & Co., Inc. (as of Aug. 7, 2020).